Article Details
Retrieved on: 2021-09-01 16:56:11
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Pfizer's JADE DARE phase 3 trial met its coprimary and key secondary efficacy endpoints. Pfizer has announced that its phase 3, 26-week, randomized, double- ...
Article found on: www.dermatologytimes.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here